biosimilar

(redirected from subsequent entry biologic)
Also found in: Medical.

bi·o·sim·i·lar

 (bī′ō-sĭm′ə-lər)
adj.
Highly similar in function and effect to an existing biological product, especially to a biologic that has already been clinically tested and approved for use.
n.
A biological product that is biosimilar to an existing product, especially to a biologic.
References in periodicals archive ?
Aligning Canadian drug prices with international levels, especially for Remicade, and using less expensive alternative therapies, such as biosimilars, also known as subsequent entry biologics, would result in lower drug costs for Canadians.
As guidelines have been developed, terms such as "subsequent entry biologics" (Canada), "biocomparables" (Mexico) and "similar biotherapeutic products" (World Health Organisation) have been used, but the majority of issued international guidelines have settled on "biosimilar" to describe products whose quality, safety and efficacy are designed to be comparable to the originator or reference product.